Kainos Medicine, Inc. (KOSDAQ:284620)

Innovid Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2019	FY 2018	FY 2017	FY 2014	FY 2013
Period Ending	Mar 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2014	Dec 31, 2013
Net Income	120.81	160.16	77.89	-88.88	-2,068	-5,800
Depreciation & Amortization	-	-	-	-	41.8	110.09
Loss (Gain) From Sale of Assets	-	-	-	-	-15.3	54.39
Asset Writedown & Restructuring Costs	-	-	-	-	-	6,719
Loss (Gain) on Equity Investments	-	-	-	-	3.79	-27.26
Other Operating Activities	51.52	27.49	-104.96	75.79	0.18	-3,338
Change in Unearned Revenue	-	-	-	-	69.18	-100
Change in Other Net Operating Assets	-2.53	-1.91	5.06	-14.14	-101.69	-898.69
Operating Cash Flow	169.79	185.74	-22.01	-27.23	-2,071	-3,280
Capital Expenditures	-	-	-	-	-1.8	-0.9
Sale of Property, Plant & Equipment	-	-	-	-	25	-
Sale (Purchase) of Intangibles	-	-	-	-	-5.69	-5.8
Investment in Securities	-	-	-	-	552.7	-317.86
Other Investing Activities	-135.53	-135.53	-9,000	-	88.11	173.87
Investing Cash Flow	-135.53	-135.53	-9,000	-	658.32	-150.69
Issuance of Common Stock	-	-	-	-	1,333	2,397
Other Financing Activities	-	-	17,676	9,588	-	-
Financing Cash Flow	-	-	17,676	9,588	1,333	2,397
Foreign Exchange Rate Adjustments	-	-	-	-	0.32	-1.73
Miscellaneous Cash Flow Adjustments	61.76	44.56	184.15	10,812	-0	-
Net Cash Flow	-123.52	-89.13	-368.31	20,289	-78.41	-1,036
Free Cash Flow	169.79	185.74	-22.01	-27.23	-2,072	-3,281
Free Cash Flow Margin	-	-	-	-	-1426.41%	-3280.83%
Free Cash Flow Per Share	26.28	34.39	-61.33	-	-235.44	-429.90
Cash Income Tax Paid	49.31	49.31	0.44	0.33	-	-
Levered Free Cash Flow	-	-	-	-	-1,165	-5,397
Unlevered Free Cash Flow	-	-	-	-	-1,165	-5,397
Change in Net Working Capital	-	-	-	-	-124.09	3,989

Updated Apr 30, 2020. Source: S&P Global Market Intelligence. Standard template. Financial Sources.